Prevention of type 2 diabetes mellitus;Prevención de la diabetes mellitus tipo 2

Endocrinologia y Nutricion

Volumn 52, Issue 2, 2005, Pages 75-81

  Vidal, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Acarbose; Diabetes mellitus; Lifestyle; Metformin; Obesity; Orlistat; Prevention

Indexed keywords

ACARBOSE; METFORMIN; PLACEBO; TETRAHYDROLIPSTATIN; TROGLITAZONE;

AGE; BODY MASS; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC DIET; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVENTIVE MEDICINE; REVIEW;

EID: 16444363702     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(05)70991-8     Document Type: Article

References (25)

1. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
2. Diabetes Prevention Research Group. Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med. 2002;346:393-403.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-7.
4. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
5. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996;45:1572-9.
6. Tamayo-Marco B, Faure-Nogueras E, Roche-Asensio MJ, Rubio-Calvo E, Sánchez-Oriz E, Salvador-Olivan JA. Prevalence of diabetes and impaired glucose tolerance in Aragon, Spain. Diabetes Care. 1997;20:534-6.
7. Castell C, Tresserras R, Serra J, Goday A, Lloveras G, Salleras L. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract. 1999;43:33-40.
8. Botas P, Delgado E, Castano G, Díaz de Grenu C, Prieto J, Díaz-Cadorniga FJ. Comparison of the diagnostic criteria for diabetes mellitus, WHO-1985, ADA-1997 and WHO-1999 in the adult population of Asturias (Spain). Diabet Med. 2003;20:904-8.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
10. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-31.
11. Oliveira-Fuster G, Olvera-Márquez P, Carral-Sanlaureano F, González-Romero S, Aguilar-Diosdado M, Soriguer-Escofet F. Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain. Diabetes Care. 2004;27:1904-9.
12. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 1997;20:1744-66.
13. Harris MI. Impaired glucose tolerance. Prevalence and conversion to NIDDM. Diabet Med. 1996;13 Supl 2:S9-S11.
14. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27 Supl 1:S47-54.
15. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708-23.
16. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004;53:2095-100.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
18. American Diabetes Associaton. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2004;27:S5-S10.
19. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr. 2004;80:257-63.
20. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord. 2002;26 Supl 4:S25-8.
21. Qiao Q, Lindstrom J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med. 2003;20:1027-33.
22. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-81.
23. Maggioni AP, Latini R. RAAS Inhibitors in the cardiovascular continuum: what is still missing? Cardiovasc Drugs Ther. 2004;18:311-20.
24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94.
25. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304-21.